212 related articles for article (PubMed ID: 27058620)
21. Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ-based Comparison With PET/CT.
Pujara AC; Raad RA; Ponzo F; Wassong C; Babb JS; Moy L; Melsaether AN
Breast J; 2016 May; 22(3):264-73. PubMed ID: 26843433
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
[TBL] [Abstract][Full Text] [Related]
23. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.
Schirrmeister H; Guhlmann A; Elsner K; Kotzerke J; Glatting G; Rentschler M; Neumaier B; Träger H; Nüssle K; Reske SN
J Nucl Med; 1999 Oct; 40(10):1623-9. PubMed ID: 10520701
[TBL] [Abstract][Full Text] [Related]
25. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma.
Tiwari BP; Jangra S; Nair N; Tongaonkar HB; Basu S
Indian J Cancer; 2010; 47(4):385-90. PubMed ID: 21131750
[TBL] [Abstract][Full Text] [Related]
26. Multiparametric PET and MRI of myocardial damage after myocardial infarction: correlation of integrin αvβ3 expression and myocardial blood flow.
Makowski MR; Rischpler C; Ebersberger U; Keithahn A; Kasel M; Hoffmann E; Rassaf T; Kessler H; Wester HJ; Nekolla SG; Schwaiger M; Beer AJ
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1070-1080. PubMed ID: 32970218
[TBL] [Abstract][Full Text] [Related]
27. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
28. Diet intervention reduces uptake of αvβ3 integrin-targeted PET tracer 18F-galacto-RGD in mouse atherosclerotic plaques.
Saraste A; Laitinen I; Weidl E; Wildgruber M; Weber AW; Nekolla SG; Hölzlwimmer G; Esposito I; Walch A; Leppänen P; Lisinen I; Luppa PB; Ylä-Herttuala S; Wester HJ; Knuuti J; Schwaiger M
J Nucl Cardiol; 2012 Aug; 19(4):775-84. PubMed ID: 22527796
[TBL] [Abstract][Full Text] [Related]
29. Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.
Spick C; Polanec SH; Mitterhauser M; Wadsak W; Anner P; Reiterits B; Haug AR; Hacker M; Beheshti M; Karanikas G
Anticancer Res; 2015 Dec; 35(12):6787-91. PubMed ID: 26637897
[TBL] [Abstract][Full Text] [Related]
30. The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer.
Yi C; Yu D; Shi X; Zhang X; Luo G; He Q; Zhang X
Nucl Med Commun; 2016 Mar; 37(3):239-46. PubMed ID: 26588068
[TBL] [Abstract][Full Text] [Related]
31. Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis.
Wetter A; Lipponer C; Nensa F; Heusch P; Rübben H; Schlosser TW; Pöppel TD; Lauenstein TC; Nagarajah J
Ann Nucl Med; 2014 Jun; 28(5):405-10. PubMed ID: 24595461
[TBL] [Abstract][Full Text] [Related]
32. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.
Liu S
Mol Pharm; 2006; 3(5):472-87. PubMed ID: 17009846
[TBL] [Abstract][Full Text] [Related]
33. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning.
Garcia JR; Jorcano S; Soler M; Linero D; Moragas M; Riera E; Miralbell R; Lomeña F
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):342-50. PubMed ID: 24844254
[TBL] [Abstract][Full Text] [Related]
34. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
35. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [
Vaishampayan UN; Tehrani OS; Lawhorn-Crews JM; Heilbrun LK; Dobson K; Smith D; Dickow B; Shields AF
Mol Imaging Biol; 2017 Dec; 19(6):810-816. PubMed ID: 28289967
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
37. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
38. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression.
Beer AJ; Haubner R; Wolf I; Goebel M; Luderschmidt S; Niemeyer M; Grosu AL; Martinez MJ; Wester HJ; Weber WA; Schwaiger M
J Nucl Med; 2006 May; 47(5):763-9. PubMed ID: 16644745
[TBL] [Abstract][Full Text] [Related]
39. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
40. Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion.
Bombardieri E; Setti L; Kirienko M; Antunovic L; Guglielmo P; Ciocia G
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):381-99. PubMed ID: 26337240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
